Inhaled pre-prandial human insulin with the AERx iDMS plus metformin versus rosiglitazone plus metformin in type 2 diabetes: a 26-week, open-label, multicentre, randomised, parallel trial to investigate efficacy and safety
Phase of Trial: Phase III
Latest Information Update: 14 Jan 2008
At a glance
- Drugs Insulin; Rosiglitazone
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Novo Nordisk
- 14 Jan 2008 Novo Nordisk has discontinued further development of AERx.
- 07 Mar 2007 New trial record.